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Abstract
Background: The effect of non-steroidal anti-inflammatory drugs (NSAIDs) for reduced platelet
aggregation and thromboxane A2 synthesis has been well documented. However, the influence on
platelet function is not fully explained. Aim of this study was to examine the influence of the COX-
1 inhibiting NSAIDs, diclofenac and metamizol on platelet activation and leukocyte-platelet
complexes, in vitro. Surface expression of GPIIb/IIIa and P-selectin on platelets, and the percentage
of platelet-leukocyte complexes were investigated.
Methods: Whole blood was incubated with three different concentrations of diclofenac and
metamizol for 5 and 30 minutes, followed by activation with TRAP-6 and ADP. Rates of GPIIb/IIIa
and P-selectin expression, and the percentage of platelet-leukocyte complexes were analyzed by a
flow-cytometric assay.
Results: There were no significant differences in the expression of GPIIb/IIIa and P-selectin, and in
the formation of platelet-leukocyte complexes after activation with ADP and TRAP-6, regarding
both the time of incubation and the concentrations of diclofenac and metamizol.
Conclusions:  Accordingly, the inhibitory effect of diclofenac and metamizol on platelet
aggregation is not related to a reduced surface expression of P-selectin and GPIIb/IIIa on platelets.
Background
Hemostasis is characterized by a close interaction of vas-
cular, plasmatic and cell components. Under physiologi-
cal conditions, each of these biological systems is in a state
of equilibrium. Interferences induced by medical drugs
can lead to uncontrollable peri- and postoperative hemor-
rhage. Platelets act on the process of coagulation in vari-
ous ways and therefore play a pivotal role in hemostasis.
The activation of platelets is associated with a change in
the expression of surface antigens, of which P-selectin and
the fibrinogen receptor complex GIIb/IIIa are of special
importance.
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P-selectin is an adhesion molecule which is synthesized
by megakaryocytes and incorporated in the platelet α-
granules. After stimulation of platelets, P-selectin is rap-
idly transported to the cell surface by fusion of the α-gran-
ule membrane with the plasma membrane. P-selectin is
involved in the adhesion of activated platelets to endothe-
lium, monocytes and granulocytes. Findings from previ-
ous studies have shown that platelet activation is a potent
stimulus for platelet-neutrophil complex formation and
neutrophil function [1,2].
Like P-selectin, GPIIb/IIIa is an α-granule membrane pro-
tein [3]. Activation increases the number of GPIIb/IIIa
complexes expressed on the platelet surface and trans-
forms GPIIb/IIIa complexes to a state that is able to bind
to fibrinogen or von Willebrand factor [4], which is the pre-
requisite for platelet aggregation. It becomes increasingly
apparent that platelet-leukocyte complexes have an
important function. These complexes are mediated by
platelet CD62P expression and leukocyte β2 integrins or
PSGL-1 and play a prominent role in hemostasis and
inflammation [5,6]. Neutrophils with platelets attached
have been described to display a more activated pattern of
adhesion molecule expression, to produce more superox-
ide, and to ingest more bacteria than neutrophils not asso-
ciated with platelets [2]. Accordingly, the percentage of
platelet-leukocyte complexes reflects the state of platelet
and leukocyte activation.
The pharmacological mechanism of non-steroidal anti-
inflammatory drugs (NSAIDs) is the intracellular interac-
tion with the cyclooxygenase (COX), one of the central
enzymes in the eicosanoid metabolism. NSAIDs inhibit
the synthesis of cyclooxygenase and subsequently lead to
a decreased production of prostaglandines [7] and other
substances, interfering with platelet activation, e.g. throm-
boxane A2 (TXA2) [8].
There are controversial results regarding the influence of
diclofenac on hemostasis [9-11]. For metamizol, a dose-
dependent effect on platelet aggregation through the inhi-
bition of TXA2 synthesis in platelets has been reported
[12,13]. To further study the effect of the NSAIDs
diclofenac and metamizol on platelet function, we have
investigated the surface expression of GPIIb/IIIa and P-
selectin as well as the formation of platelet-monocyte/
granulocyte complexes, using a flow cytometric
technique.
Methods
Following approval of the local Ethics Committee, 3 ml
whole blood was collected in sodium citrate disposable
blood sampling tubes (0.3 mL, 0.106 mol L-1,
Monovette®, Sarstedt, Nümbrecht, Germany) from 20
healthy blood donors. Blood samples were drawn from a
peripheral vein, using 18-gauge needles. To keep ex vivo
platelet activation as low as possible, blood samples were
processed within 30 minutes after drawing.
Diclofenac, kindly supplied for experimental purposes by
Merck dura (pure pulverized, Merck dura GmbH, Darm-
stadt, Germany) was added in final concentrations of 150
ng ml-1, 1500 ng ml-1 and 3000 ng ml-1. Metamizol (Rati-
opharm GmbH, Ulm, Germany) was added in final con-
centrations of 6 µg ml-1, 60 µg ml-1 and 120 µg ml-1. Both
drugs were dissolved with phosphate-buffered saline.
IgG isotype controls were applied to detect non-specific
staining. Samples were incubated with diclofenac and
metamizol at 37°C for 5 and 30 minutes, respectively,
with gentle agitation. Controls did not contain drugs. For
platelet identification and glycoprotein IIb/IIIa (GPIIb/
IIIa) expression changes samples were stained with 6 µl
anti-GPIIb/IIIa PE (phycoerythin)-conjugated mono-
clonal antibody (CD41-PE, clone P2, Beckman-Coulter,
Krefeld, Germany). To detect platelet activation and leu-
kocyte-platelet complex formation under basal condi-
tions, samples were stained with 6 µl FITC (fluorescein
isothiocyanate) – monoclonal antibody against P-selectin
(CD62P-FITC, clone CLB/Thromb/6, Beckman-Coulter)
or against leukocytes (CD45-FITC, clone KC56, Beckman-
Coulter), respectively. Samples were incubated at 37°C
for 10 minutes in the dark. To evaluate platelet reactivity,
samples were activated with 6 µM TRAP-6 (Thrombin
Receptor Activating Peptide-6, Bachem, Heidelberg, Ger-
many) or 10 µM ADP (Adenosine Diphosphat, Sigma
Chemicals, Deisenhofen, Germany) for 10 minutes at
37°C before staining with the monoclonal antibodies.
After addition of 2 mL phosphate-buffered saline contain-
ing 1% bovine serum albumin, activation was stopped by
transferring the sample onto ice.
Flow cytometry analysis
The flow cytometer was equipped with an argon laser with
a wave length of 488 nm (Epics XL®, Beckman-Coulter).
For each sample a minimum of 25,000 platelets or 15,000
leukocytes were analysed. The green fluorescence emis-
sion for CD62P and CD45 was measured by the corre-
sponding photomultiplier (FL 1, 525 nm). The
photomultiplier for FL-2 (575 nm) was used for recogni-
tion of platelets (CD41-PE). Forward scatter, sideward
scatter, FL 1 and FL 2 were assessed using the logarithmic
mode. Mean channel fluorescence emission was analyzed
in histograms and platelet-leukocyte complexes in dot
plots using a PC-software package (EXPO® 2.0, Beckman-
Coulter).
Whole blood assays of platelets require correct identifica-
tion and separation of platelets from erythrocytes or
debris. For this reason platelets were identified based onBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/4
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their high density expression of the specific platelet anti-
gen CD41-PE in the FSC/FL2 dot plot. The platelets were
gated by setting a polygonal gate and transferred to a FL-1
(CD62P-FITC) and FL-2 (CD41-PE) histogram. The mean
channel expression of FL-1 and FL-2 was used to deter-
mine the activation-dependent expression density of
GPIIb/IIIa and P-selectin according to TRAP-6
stimulation.
To analyze platelet-leukocyte complexes, leukocytes were
marked in a FL1-histogram according to their high CD45
expression. The CD45-positive cells were displayed in a
FSC/SSC dot plot. Dependent on their specific FSC and
SSC characteristics monocytes and granulocytes were
gated by setting a polygonal gate and were individually
displayed in FL-2 versus FSC dot plots for analysis of
platelet-monocyte and platelet-granulocyte complexes.
Statistical analysis
Histogram data were expressed as the mean channel
intensity, aggregates of platelets and leukocytes as the per-
centages of the respective sub-population (mean ± SD).
Differences between the groups were evaluated by the
analysis of variance (ANOVA) for repeated measure-
ments. P < 0.05 was considered significant.
Results
Influence of metamizol and diclofenac on GPIIb/IIIa 
receptor expression
Compared to the control (22.9 ± 8.1) the mean fluores-
cence intensity of GPIIb/IIIa antigen expression on resting
platelets after 5 minutes incubation not statistically signif-
icant influenced in either concentration (Metamizol: 6 µg
ml-1: 23.5 ± 11.5; 60 µg ml-1: 22.5 ± 10.9; 120 µg ml-1:
24.1 ± 12.1; Diclofenac: 150 ng ml-1: 23.1 ± 12.4, 1500 ng
ml-1: 22.9 ± 11.9; 3000 ng ml-1: 24.3 ± 12.3). After TRAP-
6 stimulation, we noted a non significant increased
GPIIb/IIIa expression (49.9 ± 20.5; 48.7 ± 17.7; 49.0 ±
22.3) with metamizol compared to the control (45.3 ±
16.8). ADP stimulation had no effect on GPIIb/IIIa recep-
tor expression (control: 30.7 ± 5.8 vs. 29.9 ± 3.0; 28.5 ±
3.4; 30.1 ± 3.7, respectively). Incubation with diclofenac
did not affect GPIIb/IIIa expression after TRAP-6 (41.7 ±
10.7; 44.3 ± 12.0; 42.9 ± 5.2) and ADP (29.0 ± 3.4; 28.3 ±
4.3; 28.6 ± 4.8) activation. These results were independent
of the incubation time (Fig. 1, 2).
Influence of metamizol and diclofenac on P-selectin 
receptor expression
Similar to the results of GPIIb/IIIa, P-selectin expression
on resting platelets was not influenced by metamizol (2.0
± 0.2; 1.8 ± 0.2; 2,1 ± 0.3) and diclofenac (1.9 ± 0.2; 2.1 ±
0.2; 1.7 ± 0.2) compared to control (1.9 ± 0.1). Agonist
stimulation with ADP (control: 13.7 ± 0.3 vs. 13.6 ± 0.4;
13.6 ± 0.5; 14.4 ± 0.4) or TRAP-6 (control: 18.4 ± 2.5 vs.
17.7 ± 4.2; 16.2 ± 2.9; 18.7 ± 6.4) had no significant effect
on P-selectin following supplementation with metamizol.
Comparable results were obtained for diclofenac incuba-
tion. Incubation time had no effect on P-selectin expres-
sion, either (Fig. 1, 2).
Influence of metamizol and diclofenac on the percentage 
of platelet-monocyte and -granulocyte complex formation
Metamizol as well as diclofenac did not influence the for-
mation of platelet-monocytes and platelet-granulocyte
complexes after activation with both agonists (Fig. 3, 4).
Discussion
In this study whole blood samples were incubated with
the NSAIDs diclofenac and metamizol at various concen-
trations incubation times. The activation of platelets was
induced by TRAP-6 and of ADP, respectively. The influ-
ence of both NSAIDs on platelet behaviour was examined
with regard to the expression of GPIIb/IIIa and P-selectin.
Additionally, the formation of complexes between plate-
lets and leukocytes – differentiated in granulocytes and
monocytes – was studied. Neither substance showed a
substantial influence on receptor expression and forma-
tion of complexes.
It is commonly accepted that the main mechanism for the
alteration of platelet function caused by NSAIDs is the
interference with the eicosanoid metabolism, particularly
the inhibition of the enzyme cyclooxygenase (COX). Both
substances tested in this study are non-selective COX
inhibitors with great analgesic capacity. Despite their fre-
quent clinical usage, few data exist about diclofenac and
metamizol regarding their effect on platelet receptor
expression and complex formation.
Various in vitro and ex vivo studies demonstrated a reduc-
tion of TXA2 synthesis and platelet aggregation caused by
the interference of diclofenac [15-17] and metamizol [14-
19] with COX-1. With this respect we focused on platelet
receptor expression rather than platelet aggregation.
ADP initiates a positive feedback reaction by inducing
other agonists of platelet aggregation, e.g. TXA2, which
enable a complete activation of platelets. This activation
can be observed as a biphasic process using an aggregom-
eter. In this process TXA2 acts as the substantial mediator
of irreversible aggregation. Although such a process of
platelet aggregation is unlikely to occur in vivo, it can be
assumed that the COX-dependent platelet activation by
ADP has a greater effect than the stimulation by thrombin
or TRAP-6 [20].
Previous studies suggested that ADP-mediated platelet
aggregation can be suppressed at least partially by
diclofenac [21] and metamizol [22]. By contrast, in ourBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/4
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Effects of metamizol after 5 and 30 minutes incubation on the expression of P-selectin and GPIIb/IIIa on the surface of ADP and  TRAP-6 activated platelets Figure 1
Effects of metamizol after 5 and 30 minutes incubation on the expression of P-selectin and GPIIb/IIIa on the surface of ADP and 
TRAP-6 activated platelets. Results are given as percentage of change from the control (100%) of the the mean fluorescence 
intensity (n = 20, mean ± SD).
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Effects of diclofenac after 5 and 30 minutes incubation on the expression of P-selectin and GPIIb/IIIa on the surface of ADP and  TRAP-6 activated platelets Figure 2
Effects of diclofenac after 5 and 30 minutes incubation on the expression of P-selectin and GPIIb/IIIa on the surface of ADP and 
TRAP-6 activated platelets. Results are given as percentage of change from the control (100%) of the the mean fluorescence 
intensity (n = 20, mean ± SD).
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study no substantial changes in receptor expression or
complex formation, neither by diclofenac or Metamizol,
were observed for this type of platelet aggregation. These
findings are in accordance with the study of Domínguez-
Jiménez et al. [23], who observed no reduction of GPIIb/
IIIa expression using diclofenac following ADP stimula-
tion. However, in contrast to our study they used antibod-
ies directed against neoepitopes generated by activation-
Metamizol effect after 5 and 30 minutes incubation on the percentage of granulocyte- and monocyte-platelet complexes after  stimulation with ADP and TRAP-6 Figure 3
Metamizol effect after 5 and 30 minutes incubation on the percentage of granulocyte- and monocyte-platelet complexes after 
stimulation with ADP and TRAP-6. Values are expressed as the mean ± SD (n = 20).
granulocyte-platelet complexes
0
10
20
30
40
50
60
70
80
90
control 6 µg ml-1 60 µg ml-1 120 µg ml-1 control 6 µg ml-1 60 µg ml-1 120 µg ml-1
p
e
r
c
e
n
t
a
g
e
 
o
f
 
c
o
m
p
l
e
x
e
s
monocyte-platelet complexes
0
10
20
30
40
50
60
70
80
90
control 6 µg ml-1 60 µg ml-1 120 µg ml-1 control 6 µg ml-1 60 µg ml-1 120 µg ml-1
p
e
r
c
e
n
t
a
g
e
 
o
f
 
c
o
m
p
l
e
x
e
s
no stimulation ADP TRAP-6
5 minutes 30 minutesBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/4
Page 7 of 9
(page number not for citation purposes)
dependent conformational changes in the GPIIb/IIIa
complex.
Although statistically not significant, it is apparent that
metamizol tends to inhibit P-selectin expression follow-
ing stimulation by ADP. This effect is basically weak but
increases with higher concentrations of metamizol and
Diclofenac effect after 5 and 30 minutes incubation on the percentage of granulocyte- and monocyte-platelet complexes after  stimulation with ADP and TRAP-6 Figure 4
Diclofenac effect after 5 and 30 minutes incubation on the percentage of granulocyte- and monocyte-platelet complexes after 
stimulation with ADP and TRAP-6. Values are expressed as the mean ± SD (n = 20).
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with incubation time. However, since higher metamizol
concentrations are usually not achievable in vivo, this
effect might be disregarded in the clinical situation.
The idea of a COX-independent effect on platelets is sup-
ported by the study of Andrioli and colleagues [24], who
found that diclofenac increases platelet activation proba-
bly through the inhibition of the COX pathway, leading to
a shift of the arachidonic acid metabolism to the 12-lipox-
ygenase pathway. Its metabolites 5-, 12-, and 15-hydrox-
yeicosatetraenoic acid seem to support platelet
aggregation [25]. However, the latter effect may weakened
by inhibitory effects of 12-hydroxyeicosatetraenoic acid
on TXA2-induced platelet aggregation, as proposed by
Fonlupt et al. [26], whereby the dose may be critical for
either activating or inhibiting effects [27,28].
In conclusion, our study demonstrates that at low and
even at very high doses, diclofenac and metamizol do not
lead to impaired platelet aggregation, as measured by
platelet-leukocyte adhesion, or expression of GPIIb/IIIa
and P-selectin.
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